MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$124K
Free Cash flow
-$1,355K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Net proceeds from the issuance o...
    • Stock-based compensation and exp...
    • Net proceeds from the loan
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Acquisition and development of i...
    • Accounts receivable, net
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,936
-2,402
-726
-1,821
Depreciation and amortization
56
58
64
119
Provision for bad debt
-
-
0
-
Impairment of assets
0
0
0
-
Stock-based compensation and expenses, net
747
1,009
926
730
Other items
254
20
-2,155
-1,055
Accounts receivable, net
20
24
-29
-46
Inventory
0
0
-19
-6
Deposits and advances
-23
37
25
-37
Claims and advances
-3
-10
-3
-8
Accounts payable
363
241
384
-303
Accrued and other liabilities
151
-98
258
93
Operating lease asset
-9
-2
-2
-53
Operating lease liability
0
-2
-2
-3
Net cash used in operating activities
-1,350
-1,223
-1,223
-2,090
Purchase of property, plant, and equipment
5
1
12
29
Sale of property, plant, and equipment
0
0
2
-23
Investment in short-term investment
-
-
-
25
Investment in short-term investments
-
-
50
-
Acquisition and development of intangible assets
249
169
193
297
Net cash (used in) provided by investing activities
-254
-170
-228
-374
Net proceeds from the issuance of common stock
1,039
-3,876
-
3,111
Proceeds from common stock subscribed
-
-
5,228
-
Repayment of long-term loan
-
-
1
2
Net proceeds from the loan
691
623
-
-
Net cash provided by financing activities
1,730
710
1,264
3,110
Effects of exchange rate changes on cash and cash equivalents
-2
-10
-18
5
Net decrease in cash and cash equivalents
124
-693
-205
651
Cash and cash equivalents at the beginning of the period
207
900
1,105
405
Cash and cash equivalents at the end of the period
331
207
900
1,105
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net proceeds fromthe issuance of...$1,039K (21.95%↑ Y/Y)Net proceeds fromthe loan$691K Net cash provided byfinancing activities$1,730K (103.29%↑ Y/Y)Net decrease in cashand cash...$124K (153.06%↑ Y/Y)Canceled cashflow$1,606K Stock-based compensationand expenses, net$747K (65.27%↑ Y/Y)Accounts payable$363K (611.76%↑ Y/Y)Other items$254K (1158.33%↑ Y/Y)Accrued and otherliabilities$151K (125.21%↑ Y/Y)Depreciation andamortization$56K (-60.28%↓ Y/Y)Deposits and advances-$23K (87.43%↑ Y/Y)Operating lease asset-$9K (71.88%↑ Y/Y)Claims and advances-$3K Net cash used inoperating activities-$1,350K (4.05%↑ Y/Y)Net cash (used in)provided by investing...-$254K (-143.79%↓ Y/Y)Effects of exchange ratechanges on cash and cash...-$2K (-108.00%↓ Y/Y)Canceled cashflow$1,606K Net loss-$2,936K (-83.61%↓ Y/Y)Acquisition and developmentof intangible...$249K (118.42%↑ Y/Y)Purchase of property,plant, and equipment$5K (-37.50%↓ Y/Y)Accounts receivable, net$20K (-62.26%↓ Y/Y)

IGC Pharma, Inc. (IGC)

IGC Pharma, Inc. (IGC)